[HTML][HTML] Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease, and high …
Although generally not applied as first-line treatment of multiple myeloma, allogeneic
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …
[HTML][HTML] Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and …
L Rasche, C Röllig, G Stuhler, S Danhof… - Biology of Blood and …, 2016 - astctjournal.org
Although generally not applied as first-line treatment of multiple myeloma, allogeneic
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …
[PDF][PDF] Biology of Blood and Marrow Transplantation
mortality, 2016 - researchgate.net
Although generally not applied as first-line treatment of multiple myeloma, allogeneic
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …
Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk …
L Rasche, C Röllig, G Stuhler… - Biology of blood …, 2016 - pubmed.ncbi.nlm.nih.gov
Although generally not applied as first-line treatment of multiple myeloma, allogeneic
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …
[HTML][HTML] Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and …
L Rasche, C Röllig, G Stuhler, S Danhof… - Biology of Blood and …, 2016 - tctjournal.org
Although generally not applied as first-line treatment of multiple myeloma, allogeneic
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …
Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk …
L Rasche, C Röllig, G Stuhler, S Danhof… - Biology of Blood and …, 2016 - europepmc.org
Although generally not applied as first-line treatment of multiple myeloma, allogeneic
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …
Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk …
L Rasche, C Röllig, G Stuhler, S Danhof… - Biology of Blood and …, 2016 - infona.pl
Although generally not applied as first-line treatment of multiple myeloma, allogeneic
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …